Key result
Anthracycline-induced cardiotoxicity is a serious late effect in childhood cancer survivors, and while agents like dexrazoxane show promise, valid surrogate endpoints are urgently needed for research.
Why the study?
What are the mechanisms and consequences of anthracycline cardiotoxicity in children treated for cancer?
What are the mechanisms and consequences of anthracycline cardiotoxicity in children treated for cancer?
Anthracycline-induced cardiotoxicity remains a major concern for long-term survivors of childhood cancer.
Supports heightened surveillance in survivors; leaves open validation of surrogates to advance cardioprotection trials.
More than 70 percent of children who are treated for childhood cancer can be cured. For long-term survivors, possible late effects of treatment and their consequences for the quality of life are a major concern. Cardiotoxic effects of anthracyclines are among the most frequent and serious adverse effects of the treatment of childhood cancer. Anthracyclines such as daunorubicin, epirubicin, and doxorubicin have been used for more than 30 years, and nearly 60 percent of children with cancer are currently being treated with such agents.The mechanisms behind cardiotoxic effects are not fully understood, but lipid peroxidation and the generation of . . .
No takes yet. Share an insight, caveat, or question.
Kremer et al. (2004) conducted an editorial in Childhood cancer. Anthracyclines and Dexrazoxane was evaluated. Anthracycline-induced cardiotoxicity is a serious late effect in childhood cancer survivors, and while agents like dexrazoxane show promise, valid surrogate endpoints are urgently needed for research.